The Gulf Familial Hypercholesterolemia Registry (Gulf FH): Design, Rationale and Preliminary Results.
Adolescent
Adult
Aged
Biomarkers
/ blood
Cross-Sectional Studies
Female
Genetic Predisposition to Disease
Humans
Hyperlipoproteinemia Type II
/ diagnosis
Lipids
/ blood
Longitudinal Studies
Male
Middle Aged
Middle East
/ epidemiology
Phenotype
Preliminary Data
Prevalence
Prognosis
Registries
Research Design
Retrospective Studies
Risk Factors
Time Factors
Young Adult
CHD
Familial hypercholesterolemia
Middle East
cardiovascular diseases
consanguinity
registry.
Journal
Current vascular pharmacology
ISSN: 1875-6212
Titre abrégé: Curr Vasc Pharmacol
Pays: United Arab Emirates
ID NLM: 101157208
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
08
2018
revised:
01
10
2018
accepted:
01
10
2018
pubmed:
6
10
2018
medline:
29
9
2020
entrez:
6
10
2018
Statut:
ppublish
Résumé
To determine the prevalence, genetic characteristics, current management and outcomes of familial hypercholesterolaemia (FH) in the Gulf region. Adult (18-70 years) FH patients were recruited from 9 hospitals and centres across 5 Arabian Gulf countries. The study was divided into 4 phases and included patients from 3 different categories. In phase 1, suspected FH patients (category 1) were collected according to the lipid profile and clinical data obtained through hospital record systems. In phase 2, patients from category 2 (patients with a previous clinical diagnosis of FH) and category 1 were stratified into definitive, probable and possible FH according to the Dutch Lipid Clinic Network criteria. In phase 3, 500 patients with definitive and probable FH from categories 1 and 2 will undergo genetic testing for 4 common FH genes. In phase 4, these 500 patients with another 100 patients from category 3 (patients with previous genetic diagnosis of FH) will be followed for 1 year to evaluate clinical management and cardiovascular outcomes. The Gulf FH cohort was screened from a total of 34,366 patients attending out-patient clinics. The final Gulf FH cohort consisted of 3,317 patients (mean age: 47±12 years, 54% females). The number of patients with definitive FH is 203. In this initial phase of the study, the prevalence of (probable and definite) FH is 1/232. The prevalence of FH in the adult population of the Arabian Gulf region is high. The Gulf FH registry, a first-of-a-kind multi-national study in the Middle East region, will help in improving underdiagnosis and undertreatment of FH in the region.
Identifiants
pubmed: 30289081
pii: CVP-EPUB-93470
doi: 10.2174/1570161116666181005125459
pmc: PMC7040511
doi:
Substances chimiques
Biomarkers
0
Lipids
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-64Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
J Atheroscler Thromb. 2017 Oct 1;24(10):1075-1084
pubmed: 28344196
Lancet. 2015 Jan 24;385(9965):331-40
pubmed: 25282519
Eur Heart J. 2014 Aug 21;35(32):2146-57
pubmed: 25053660
Expert Rev Cardiovasc Ther. 2008 Apr;6(4):567-81
pubmed: 18402545
Heart. 2011 Jul;97(14):1175-81
pubmed: 21685482
Vasc Health Risk Manag. 2010 Nov 10;6:1023-37
pubmed: 21127699
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Open Cardiovasc Med J. 2014 Sep 25;8:88-93
pubmed: 25328551
J Med Genet. 1995 Aug;32(8):623-6
pubmed: 7473654
Clin Genet. 1976 Feb;9(2):203-33
pubmed: 174852
J Clin Lipidol. 2015 Mar-Apr;9(2):187-94
pubmed: 25911074
Curr Vasc Pharmacol. 2015;13(6):759-70
pubmed: 26311574
Acta Cardiol. 2009 Aug;64(4):439-46
pubmed: 19725435
J Clin Lipidol. 2017 Jan - Feb;11(1):260-271
pubmed: 28391894
Atherosclerosis. 2015 Jul;241(1):169-75
pubmed: 25997074
Open Cardiovasc Med J. 2017 Jul 26;11:66-75
pubmed: 28868092
Semin Vasc Med. 2004 Feb;4(1):97-104
pubmed: 15199439
Healthcare (Basel). 2015 Oct 26;3(4):1018-30
pubmed: 27417810
Eur Heart J. 2013 Dec;34(45):3478-90a
pubmed: 23956253
J Clin Lipidol. 2018 May - Jun;12(3):685-692.e2
pubmed: 29574074
Atherosclerosis. 2016 Sep;252:182-187
pubmed: 27522462
Angiology. 2014 Nov;65(10):911-8
pubmed: 24249837
Am J Epidemiol. 2004 Sep 1;160(5):407-20
pubmed: 15321837
Atherosclerosis. 2012 Feb;220(2):429-36
pubmed: 22129472
Eur Heart J. 2015 Nov 14;36(43):2996-3003
pubmed: 26330422
J Am Coll Cardiol. 2018 Aug 7;72(6):662-680
pubmed: 30071997
J Clin Invest. 2003 Jun;111(12):1795-803
pubmed: 12813012
Angiology. 2014 Nov;65(10):919-26
pubmed: 24301426
Ann Saudi Med. 2012 Jan-Feb;32(1):9-18
pubmed: 22156634
Atherosclerosis. 2004 Mar;173(1):55-68
pubmed: 15177124
PLoS One. 2017 Aug 17;12(8):e0183494
pubmed: 28817709
J Clin Endocrinol Metab. 2012 Nov;97(11):3956-64
pubmed: 22893714
Angiology. 2013 May;64(4):287-92
pubmed: 23162007
Gene. 2015 Jul 1;565(1):76-84
pubmed: 25839937
Int J Cardiol. 2016 Dec 15;225:268-283
pubmed: 27741487
Eur Heart J. 2015 Sep 21;36(36):2438-45
pubmed: 26142466
Atherosclerosis. 2015 May;240(1):190-6
pubmed: 25797312
Atherosclerosis. 2012 Aug;223(2):262-8
pubmed: 22398274
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Clin Chem. 2018 Feb;64(2):355-362
pubmed: 29038147